Literature DB >> 9294777

Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat.

U M Kabadi1, R Cech.   

Abstract

BACKGROUND: The natural course in subjects manifesting normal serum thyroxine (T4), and triiodothyronine (T3), with an elevated thyrotropin (TSH) level demonstrated two distinct outcomes, one progressing to well defined hypothyroidism as expressed by onset of subnormal T4, T3 and a further rise in TSH and the other remaining in the same state. However, thyroid hormone concentrations at the time of diagnosis fail to distinguish between the two groups. Therefore, we examined the influence of alteration in circulating TSH levels on thyroid gland function at the time of diagnosis in subjects with this syndrome to assess the role of pituitary thyroid axis in these different outcomes.
METHODS: 24 hour 131I thyroidal uptake was determined in 14 men and 3 women manifesting normal T4, T3 and elevated TSH prior to and again after 1) subcutaneous administration of bovine TSH, 10 units daily for 3 days and 2) daily oral administration of L-triiodothyronine 75 micrograms for 7 days in a randomized sequence at interval of 4 weeks. Subjects were then followed for up to 16 years to assess the natural course.
RESULTS: Basal 24 hour 131I uptake values were within the normal range (10-35%) in all subjects and increased on TSH administration and declined following LT3 administration. However, in eight subjects, these responses were markedly lower (< 20%) when compared with the minimum change (50%) noted in normal volunteers. These subjects progressed to manifest hypothyroidism requiring LT4 therapy within two years as reflected by a progressive decrease to subnormal T4 levels with a further rise in serum TSH. The remaining nine subjects, demonstrated normal responses (> 50%) and only one of these became hypothyroid during the follow-up period of 16 years.
CONCLUSION: All subjects with normal T4 and T3 with elevated TSH do not manifest "subclinical or evolving hypothyroidism". Two distinct populations seem to exist, one with inhibited pituitary thyroid axis progressing to hypothyroidism or true "subclinical hypothyroidism" at the time of diagnosis and the other with normal pituitary thyroid axis, a state of euthyroidism with "reset thyrostat" at a higher TSH concentration, a state probably persisting for their remaining life span.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294777     DOI: 10.1007/BF03350310

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  37 in total

1.  The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease.

Authors:  R Wilson; J H McKillop; G T Crocket; C Pearson; C Jenkins; F Burns; A K Burnett; J A Thomson
Journal:  Clin Endocrinol (Oxf)       Date:  1991-05       Impact factor: 3.478

2.  Artifactual elevation of thyroid-stimulating hormone.

Authors:  J M Wood; D L Gordon; A N Rudinger; M M Brooks
Journal:  Am J Med       Date:  1991-02       Impact factor: 4.965

3.  A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism.

Authors:  E Nyström; K Caidahl; G Fager; C Wikkelsö; P A Lundberg; G Lindstedt
Journal:  Clin Endocrinol (Oxf)       Date:  1988-07       Impact factor: 3.478

Review 4.  The use and misuse of thyroid hormone.

Authors:  E Roti; R Minelli; E Gardini; L E Braverman
Journal:  Endocr Rev       Date:  1993-08       Impact factor: 19.871

5.  Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone.

Authors:  P Beck-Peccoz; S Amr; M M Menezes-Ferreira; G Faglia; B D Weintraub
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

6.  Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy.

Authors:  P Caron; C Calazel; H J Parra; M Hoff; J P Louvet
Journal:  Clin Endocrinol (Oxf)       Date:  1990-10       Impact factor: 3.478

Review 7.  Thyroxine supplementation. Method for the prevention of clinical hypothyroidism.

Authors:  J Tibaldi; U S Barzel
Journal:  Am J Med       Date:  1985-08       Impact factor: 4.965

8.  Thyroid failure in the elderly. Microsomal antibodies as discriminant for therapy.

Authors:  M J Rosenthal; W C Hunt; P J Garry; J S Goodwin
Journal:  JAMA       Date:  1987-07-10       Impact factor: 56.272

Review 9.  Levothyroxine therapy in patients with thyroid disease.

Authors:  S J Mandel; G A Brent; P R Larsen
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

10.  Screening of an elderly female population for hypo- and hyperthyroidism by use of a thyroid hormone panel.

Authors:  M Falkenberg; B Kågedal; A Norr
Journal:  Acta Med Scand       Date:  1983
View more
  1 in total

Review 1.  Management of the unexpected result: compensated hypothyroidism.

Authors:  R Benediktsson; A D Toft
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.